Consistent with the above findings pertaining to LC3-II accumulation, the percentage of LC3 puncta-positive cells in the green fluorescent protein (GFP)-positive cell population also increased significantly in sorafenib-treated HCC cells compared with control cells (Fig. 1c). The gene discussed is MAP1LC3A; the disease is hepatocellular carcinoma.